GlassScriptPhysician profile
Nidia L Chediak
NPI 1427061712
$687.70
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $278 · 2021: $160 · 2022: $11.94.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $302.07 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $87.04 | 2019-2021 | |
| Allergan, INC. | $64.71 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.31 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $29.11 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $22.76 | 2021 | |
| Pfizer INC. | $22.30 | 2019 | |
| Abbvie INC. | $21.82 | 2021 | |
| Abbott Laboratories | $20.51 | 2020 | |
| Astellas Pharma US INC | $18.93 | 2020 | |
| Novo Nordisk INC | $15.70 | 2019 | |
| Eisai INC. | $14.25 | 2021 | |
| Amgen INC. | $13.19 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nidia Chediak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.